Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid Olfactory Test Shows Potential as Screening Tool for COVID-19

By LabMedica International staff writers
Posted on 20 Jul 2021
A study that evaluated the feasibility of a novel, objective olfactory test as part of an initial screening for COVID-19 in adults with unknown disease status has concluded that olfactory dysfunction (OD) is one of the earliest and strongest predictors of COVID-19 infection, and thus is promising as a disease screening tool.

In the prospective, cross-sectional study, researchers at University of California, San Diego (La Jolla, CA, USA) enrolled healthy adults (aged ≥ 18 years) from a single college campus COVID-19 screening site. More...
Participants were screened for OD using a novel scent card (SAFER Diagnostics) followed immediately by polymerase chain reaction (PCR) testing for SARS-CoV-2 from nasopharyngeal swabs. The SAFER card contained a single scent in a scratch-and-sniff label that the participant identified from 8 answer options: lemon, grape, floral, blueberry, banana, mint, unsure, or no scent. Answers were processed electronically via a QR code. An incorrect choice was classified as OD. Participant demographics, medical history, COVID-19 symptoms, and subjective smell function on a binary and 10-point visual analog scale (VAS, with 0 indicating no sense of smell and 10 indicating normal sense of smell) were also collected.

A total of 163 participants were prospectively screened for OD using the scent card followed by SARS-CoV-2 PCR testing. Of those who tested PCR-positive for COVID-19, 75% (12 out of 16) failed olfactory screening compared with 4.8% (7 out of 147) among those testing PCR-negative for COVID-19. The sensitivity, specificity, positive predictive value, and negative predictive value of the scent card in detecting those with COVID-19 were 75.0%, 95.2%, 63.2%, and 97.2%, respectively. Including the symptom fatigue along with OD achieved 93.8% sensitivity and 89.8% specificity in disease screening. The addition of fever and cough did not further increase sensitivity.

While only 37.5% (6 out of 16) of COVID-19 test-positive participants reported subjective anosmia, 75% failed screening with the scent card. A failed scent card screen was the greatest predictor of COVID-19 positivity (odds ratio [OR], 80.24; 95% CI, 14.77-435.90) when compared with other symptoms including cough, fever, fatigue, and a history of COVID-19 exposure. Thus, the study demonstrated that a rapid psychophysical olfaction test is feasible as a screening tool for COVID-19.

Related Links:
University of California, San Diego


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

New Insights Into Fetal DNA Could Improve Non-Invasive Prenatal Testing

Non-invasive prenatal testing is widely used to screen pregnancies for genetic conditions by analyzing DNA fragments in maternal blood. Although it offers a safer alternative to invasive procedures such... Read more

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.